세계의 모노 백신 시장

Global Mono Vaccines Market to Reach US$12.2 Billion by 2030

The global market for Mono Vaccines estimated at US$10.2 Billion in the year 2024, is expected to reach US$12.2 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Meningococcal Vaccine, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$5.2 Billion by the end of the analysis period. Growth in the Japanese Encephalitis Vaccine segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 5.8% CAGR

The Mono Vaccines market in the U.S. is estimated at US$2.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Mono Vaccines Market - Key Trends & Drivers Summarized

Why Are Mono Vaccines Still Relevant in Modern Immunization Strategies?

Mono vaccines, which are designed to immunize against a single pathogen, remain an essential component of global vaccination programs. These vaccines are widely used in both routine immunization schedules and targeted public health campaigns. Their relevance is especially clear in early childhood immunization, travel medicine, and outbreak control where specific disease protection is required. Common mono vaccines include those for measles, hepatitis B, influenza, tetanus, and rabies.

Mono vaccines offer precise protection without exposing the immune system to multiple antigens simultaneously. This is particularly important in certain clinical situations, such as post-exposure prophylaxis or when tailoring immunization based on patient history, allergies, or contraindications. Health authorities continue to rely on mono vaccines for phased immunization schedules, booster doses, and targeted interventions in disease elimination efforts.

How Is Technology Influencing Mono Vaccine Development and Production?

Technological advancements in vaccine development have improved the safety, stability, and effectiveness of mono vaccines. Modern production techniques include recombinant DNA technology, virus-like particle platforms, and mRNA-based development, all of which contribute to improved immune response and reduced side effects. Innovations in adjuvants and delivery systems are also enhancing antigen presentation and long-term immunity.

Cold chain optimization and lyophilized formulations have increased the logistical viability of mono vaccines in low-resource settings. Standardization in dosage and needle-free delivery options, such as microneedle patches and oral vaccines, are also being developed to improve compliance and ease of administration. Increasing use of cell-culture production and automation in biomanufacturing is helping scale up production efficiently and cost-effectively.

Where Is Demand Rising and Who Are the Primary End Users?

Demand for mono vaccines is increasing in pediatric healthcare, travel medicine, public health outreach, and veterinary applications. National immunization programs across both developed and developing countries include mono vaccines for diseases that still pose public health threats. In areas where outbreaks occur, mono vaccines are rapidly deployed to control disease spread and protect vulnerable populations.

Hospitals, clinics, and government health departments are the primary end users, alongside non-governmental organizations running disease control campaigns. Travelers and healthcare workers often require mono vaccines specific to regional disease risks. In veterinary medicine, mono vaccines are used to prevent individual diseases in livestock and companion animals, supporting both animal welfare and food safety.

What Factors Are Driving Growth In The Mono Vaccines Market?

Growth in the mono vaccines market is driven by several factors including persistent disease burdens, regulatory focus on targeted immunization, and the need for flexible vaccination options. Outbreaks of diseases such as measles, hepatitis, and rabies continue to sustain demand for rapid, single-antigen immunization. Rising awareness about disease-specific risks and expansion of adult immunization programs are also contributing to growth.

Technological progress in vaccine design, more efficient production methods, and public-private collaborations are supporting broader access to affordable and effective mono vaccines. Programs focused on eliminating specific infectious diseases also depend heavily on mono vaccine deployment. As healthcare systems emphasize precision immunization and post-exposure management, mono vaccines are expected to maintain a strong position within global vaccine portfolios.

SCOPE OF STUDY:

The report analyzes the Mono Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine, Other Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AstraZeneca Plc
• Bavarian Nordic A/S
• Biological E Limited
• CanSino Biologics Inc.
• CSL Seqirus (CSL Limited)
• Daiichi Sankyo Co., Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Panacea Biotec Ltd
• Pfizer Inc.
• Sanofi Pasteur (Sanofi S.A.)
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Valneva SE
• VBI Vaccines Inc.
• Zydus Lifesciences Ltd. (Zydus Cadila)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mono Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Focus on Targeted Immunization Strategies Propels Demand for Mono Vaccines
  • Increasing Prevalence of Preventable Infectious Diseases Strengthens Use of Single-Antigen Vaccines
  • Expansion of National Immunization Programs Drives Procurement of Mono Vaccines for Mass Administration
  • Demand for Simplified Dosing and Lower Reactogenicity Supports Growth in Mono Vaccine Adoption
  • Global Push for Measles and Polio Eradication Sustains Long-Term Demand for Disease-Specific Vaccines
  • Growing Preference for Controlled Immune Response Fuels Use of Mono Vaccines in Pediatric Applications
  • Advancements in Antigen Isolation and Stabilization Enhance Efficacy of Mono Vaccine Formulations
  • Demand from Immunocompromised Patient Populations Spurs Use of Targeted Single-Disease Vaccines
  • Increasing R&D in Emerging Diseases Strengthens Market for Rapid-Response Mono Vaccine Platforms
  • Expansion of Cold Chain Infrastructure in Developing Regions Enables Wider Access to Single-Antigen Vaccines
  • Integration into Routine Childhood Vaccination Schedules Ensures Steady Public Sector Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mono Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Meningococcal Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Japanese Encephalitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Hepatitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Yellow Fever Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• JAPAN
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Japan Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: Japan 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• CHINA
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 29: China Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: China Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: China 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• EUROPE
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• FRANCE
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: France Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: France 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• GERMANY
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 41: Germany Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Germany Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Germany 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Italy Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Italy 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 47: UK Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: UK Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: UK 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 50: Spain Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Spain Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Spain 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 53: Russia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Russia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Russia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Rest of Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Rest of Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Asia-Pacific 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 65: Australia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Australia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Australia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• INDIA
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 68: India Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: India Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: India 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 71: South Korea Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: South Korea Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: South Korea 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Rest of Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 77: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Latin America Historic Review for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Latin America 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 80: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 83: Argentina Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Argentina Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Argentina 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 86: Brazil Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Brazil Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Brazil 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 89: Mexico Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Mexico Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Mexico 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Rest of Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 95: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 96: Middle East Historic Review for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Middle East 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 98: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 101: Iran Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Iran Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Iran 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 104: Israel Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Israel Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Israel 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Saudi Arabia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Saudi Arabia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 110: UAE Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UAE Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UAE 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Rest of Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Rest of Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
• AFRICA
  • Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 116: Africa Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Africa Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Africa 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030

IV. COMPETITION